FDA Approves Additional Treatment for Adults and Adolescents with Hemophilia A or B and Inhibitors

April 1st, 2020

The U.S. Food and Drug Administration today approved Sevenfact [coagulation factor VIIa (recombinant)-jncw] for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors (neutralizing antibodies). Sevenfact contains an active ingredient expressed in genetically engineered rabbits.

Denis DELVAL is appointed CEO of LFB SA

On December 20th, a decree from the President of France was published in Le Journal Officiel* appointing Denis DELVAL CEO of LFB S.A. This decree follows the General Meeting of LFB SA and the meeting of its Board of Directors, which both took place on December 4th, 2017.

Denis DELVAL is also appointed, CEO of LFB BIOMEDICAMENTS and President of LFB BIOTECHNOLOGIES as of December 4th, following Christian BÉCHON and Denis SOUBEYRAN’s departures.

LFB S.A. Receives Go Ahead From Data Monitoring Committee to Expand The Global PERSEPT Phase 3 Program of LR769 in Hemophilia A or B Patients with Inhibitors

PARIS, France, March 24, 2015 —LFB SA announced today, through its rEVO Biologics subsidiary, that after the planned interim analysis of the PerSept 1 safety and efficacy data by the independent Data Monitoring Committee (DMC), the DMC recommended that the study proceed as planned and also that LFB should expand the global PerSept Phase 3 program. 

LFB S.A. Announces Achievement of Patient Enrollment Target for PerSept 1 Program for the Evaluation of Recombinant Factor Seven Efficacy by Prospective Clinical Trials

PARIS, France, December 17, 2014 — LFB S.A. announced today the achievement of patient enrollment target for PERSEPT 1, a multinational Phase 3 clinical trial of LR769, a novel recombinant form of human Factor VIIa, in adolescent and adult congenital hemophilia A or B patients with inhibitors.

This Phase 3 trial study is being sponsored by LFB S.A.’s US subsidiary.